PEDIATRIC HEMATOLOGY AND ONCOLOGY

Scope & Guideline

Uniting researchers and practitioners for a healthier future.

Introduction

Immerse yourself in the scholarly insights of PEDIATRIC HEMATOLOGY AND ONCOLOGY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0888-0018
PublisherTAYLOR & FRANCIS INC
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1984 to 2024
AbbreviationPEDIATR HEMAT ONCOL / Pediatr. Hematol. Oncol.
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106

Aims and Scopes

Pediatric Hematology and Oncology focuses on the comprehensive understanding and treatment of blood disorders and cancers in children. The journal aims to disseminate innovative research, clinical findings, and reviews that improve the knowledge and practices within this specialized field.
  1. Pediatric Hematology:
    Research on various hematological disorders affecting children, including anemia, sickle cell disease, and hemophilia, with an emphasis on pathophysiology, treatment modalities, and long-term outcomes.
  2. Oncological Studies:
    Focused studies on pediatric cancers, including leukemia, lymphoma, and solid tumors, exploring diagnosis, treatment strategies, clinical trials, and survivorship.
  3. Transplantation and Cellular Therapies:
    Investigation into hematopoietic stem cell transplantation and other cellular therapies as treatment options for pediatric patients with severe hematological malignancies.
  4. Genetic and Molecular Research:
    Studies examining the genetic underpinnings of pediatric diseases, including genetic disorders, cancer predisposition, and the role of molecular markers in treatment responses.
  5. Supportive Care and Quality of Life:
    Research addressing supportive care measures, psychosocial aspects, and quality of life outcomes for pediatric patients and their families throughout treatment and survivorship.
  6. International Health and Disparities:
    Exploration of the challenges and outcomes of pediatric hematology and oncology in low- and middle-income countries, focusing on access to care and treatment disparities.
The journal has seen a rise in interest in several innovative and critical areas of research that reflect the evolving landscape of pediatric hematology and oncology. These emerging themes are crucial in shaping future research directions and clinical practices.
  1. Precision Medicine and Genetic Testing:
    An increasing number of papers focus on the application of genetic testing and precision medicine approaches to tailor treatments for pediatric patients, indicating a significant trend towards personalized healthcare.
  2. Impact of COVID-19 on Pediatric Patients:
    Research examining the effects of the COVID-19 pandemic on pediatric hematology and oncology patients is on the rise, highlighting the need for understanding how global health crises affect care delivery and patient outcomes.
  3. Innovative Supportive Care Strategies:
    Emerging studies are focusing on supportive care interventions, including psychosocial support and palliative care, which are crucial for improving the quality of life for pediatric patients and their families.
  4. Long-Term Outcomes and Survivorship:
    There is a growing emphasis on the long-term health outcomes and survivorship issues faced by pediatric cancer survivors, reflecting a shift towards recognizing the importance of post-treatment quality of life.
  5. International Collaborative Research:
    An increase in multicenter and international studies indicates a trend towards collaborative research efforts, aiming to address global disparities in pediatric cancer care and outcomes.

Declining or Waning

While certain research areas continue to thrive, others appear to be declining in prominence within the journal. This may reflect shifting priorities in pediatric hematology and oncology or changes in research funding and interest.
  1. Traditional Chemotherapy Approaches:
    There seems to be a decrease in studies focusing solely on conventional chemotherapy regimens, as newer targeted therapies and immunotherapies gain more attention in the treatment of pediatric cancers.
  2. Single-Center Studies:
    A noticeable decline in the publication of single-center studies suggests a shift towards multicenter collaborations that provide broader data and insights into treatment outcomes.
  3. Basic Science and Laboratory Studies:
    Research papers focusing on basic science and laboratory methodologies appear to be waning as clinical applications and translational research take precedence, highlighting a move towards practical and immediate clinical relevance.

Similar Journals

CANCER JOURNAL

Empowering Researchers to Combat Cancer Challenges.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1528-9117Frequency: 6 issues/year

CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

KLINISCHE PADIATRIE

Advancing Pediatric Care Through Innovative Research
Publisher: GEORG THIEME VERLAG KGISSN: 0300-8630Frequency: 6 issues/year

KLINISCHE PADIATRIE is a prominent academic journal published by GEORG THIEME VERLAG KG since its inception in 1972. Based in Germany, this journal serves as a valuable resource for professionals and researchers in the fields of Pediatrics, Perinatology, and Child Health. With an ISSN of 0300-8630 and E-ISSN 1439-3824, it features a rich array of peer-reviewed articles that focus on child health and development, encompassing clinical practices, therapeutic advances, and interdisciplinary approaches to pediatric care. While the journal operates on a subscription basis, its impact within the academic community is evidenced by its ranking of Q3 in Pediatrics, Perinatology, and Child Health as of 2023, and it maintains a solid standing within Q4 in Medicine (miscellaneous). The journal aims to bridge the gap between emerging research and clinical practice, providing a platform for innovative ideas that enhance pediatric care. Researchers, medical professionals, and students alike will find KLINISCHE PADIATRIE an essential addition to their academic repertoire, fostering advancements in pediatric healthcare and enriching knowledge in this vital field.

EUROPEAN JOURNAL OF HAEMATOLOGY

Elevating Knowledge in Hematology Since 1986
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

AMERICAN JOURNAL OF HEMATOLOGY

Advancing Hematological Science Through Rigorous Research
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Hematology Transfusion and Cell Therapy

Advancing knowledge in hematology and cell therapy.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Journal of Hematology

Exploring the Depths of Hematological Research
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

ANNALS OF HEMATOLOGY

Elevating knowledge with impactful research and reviews.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

Clinical Lymphoma Myeloma & Leukemia

Championing Excellence in Cancer Research
Publisher: CIG MEDIA GROUP, LPISSN: 2152-2650Frequency: 6 issues/year

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Journal of Blood Medicine

Connecting Minds: Bridging Research and Clinical Practice in Hematology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

Journal of Hematology & Oncology

Advancing the Frontiers of Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.